Effects of octreotide LAR treatment on QOL, clinical symptoms and endocrinological data in patients with acromegaly or pituitary gigantism

INTERVENTION: Octreotide LAR 10mg‐40mg CONDITION: acromegaly and pituitary gigantism PRIMARY OUTCOME: 1. QOL(SF‐36); 2. Clinical symptom(headache, sweating, arthralgia, carpal‐tunnel syndrome, and other clinical symptoms); 3. Serum GH ; 4. Serum IGF‐1 SECONDARY OUTCOME: 1. Complication(blood pressure, glucose tolerance status, dyslipidemia, and cardiovascular diseases; 2. Adverse events INCLUSION CRITERIA: 1) The age is 20 years old or more. 2) Patients diagnosed with acromegaly or pituitary gigantism according to the criteria by